These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 29214356)

  • 1. More predictive markers were identified for trastuzumab-induced cardiotoxicity.
    Altundag K
    Med Oncol; 2017 Dec; 35(1):8. PubMed ID: 29214356
    [No Abstract]   [Full Text] [Related]  

  • 2. Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab.
    Sendur MA; Aksoy S; Altundag K
    Future Oncol; 2015; 11(1):13-5. PubMed ID: 25572781
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiotoxicity: trastuzumab and cancer survivors.
    Patanè S
    Int J Cardiol; 2014 Dec; 177(2):554-6. PubMed ID: 25205483
    [No Abstract]   [Full Text] [Related]  

  • 4. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer.
    Yu AF; Yadav NU; Lung BY; Eaton AA; Thaler HT; Hudis CA; Dang CT; Steingart RM
    Breast Cancer Res Treat; 2015 Jan; 149(2):489-95. PubMed ID: 25552363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab-induced cardiomyopathy.
    Guglin M; Cutro R; Mishkin JD
    J Card Fail; 2008 Jun; 14(5):437-44. PubMed ID: 18514938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
    Fiúza M
    Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Perik PJ; Lub-De Hooge MN; Gietema JA; van der Graaf WT; de Korte MA; Jonkman S; Kosterink JG; van Veldhuisen DJ; Sleijfer DT; Jager PL; de Vries EG
    J Clin Oncol; 2006 May; 24(15):2276-82. PubMed ID: 16710024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab in the adjuvant treatment of breast cancer.
    Svetlovska D; Mardiak J; Kristova V
    Bratisl Lek Listy; 2007; 108(2):100-3. PubMed ID: 17685010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
    Singer CF; Köstler WJ; Hudelist G
    Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can modern echocardiographic techniques predict drug-induced cardiotoxicity?
    Edvardsen T
    J Am Coll Cardiol; 2011 May; 57(22):2271-2. PubMed ID: 21616288
    [No Abstract]   [Full Text] [Related]  

  • 13. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
    Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
    Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study.
    Gunaldi M; Duman BB; Afsar CU; Paydas S; Erkisi M; Kara IO; Sahin B
    J Oncol Pharm Pract; 2016 Apr; 22(2):242-7. PubMed ID: 25567518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer.
    Ürun Y; Utkan G; Yalcin B; Akbulut H; Onur H; Oztuna DG; Şenler FC; Demirkazık A; İçli F
    Exp Oncol; 2015 Mar; 37(1):53-7. PubMed ID: 25804233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Trastuzumab (Herceptin)].
    Tokuda Y; Suzuki Y; Saitou Y; Ohta M; Tajima T
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):645-52. PubMed ID: 11977556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
    Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
    J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective strategies to prevent trastuzumab-induced cardiotoxicity.
    Guo S; Tse G; Liu T
    Lancet; 2020 Feb; 395(10223):491-492. PubMed ID: 32061289
    [No Abstract]   [Full Text] [Related]  

  • 20. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
    Telli ML; Hunt SA; Carlson RW; Guardino AE
    J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.